Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.